Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05922761 · ClinicalTrials.gov registry record · Phase 2
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
A Phase 2 study of Lung Diseases and Chronic Graft Versus Host Disease, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 5
- Study locations
NCT05922761: Recruiting Phase 2 study of Lung Diseases and Chronic Graft Versus Host Disease, sponsored by Dana-Farber Cancer Institute.
NCT05922761 is a Phase 2 study of Lung Diseases and Chronic Graft Versus Host Disease that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 45 participants, below the 738-participant average among 31 other Lung Diseases trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05922761, a Phase 2 study of Lung Diseases and Chronic Graft Versus Host Disease, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this research study is to test the efficacy of a novel immunosuppressive agent, belumosudil, in allogeneic hematopoietic stem cell transplant (HSCT) recipients who have been newly diagnosed or have developing (early stage) bronchiolitis obliterans syndrome (BOS). The name of the study drugs involved in this study are: * Belumosudil (an immunotherapy) * Fluticasone (an intranasal corticosteroid) * Azithromycin (an antibiotic) * Montelukast (a leukotriene receptor antagonist) * Prednisone (a corticosteroid)
Primary Outcome
24-week ORR defined as the proportion of participants achieving BOS complete response (CR) or partial response (PR) based on change in FEV1 measurement per criteria of the 2014 NIH Consensus Conference.
Conditions Studied
Interventions
- DRUG Belumosudil
- DRUG Fluticasone
- DRUG Azithromycin
- DRUG Prednisone
- DRUG Montelukast
Study Locations (5)
Massachusetts
- Dana-Farber Cancer Institute - Boston
- Boston Children's Hospital - Boston
- Brigham and Women's Hospital - Boston
Michigan
- University of Michigan - Ann Arbor
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-05-31 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What NCT05922761 shows while recruiting
NCT05922761 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 738-participant average among 31 other Lung Diseases trials with a reported enrollment target (94% lower).
The record links to 4 conditions, with Lung Diseases appearing as the primary indexed condition, and to 5 interventions - of which Belumosudil is the first listed.
NCT05922761 lists 5 locations in 3 states (Massachusetts, Michigan, Washington).
Frequently Asked Questions
What is clinical trial NCT05922761 about?
NCT05922761 is a clinical study titled "BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)". The goal of this research study is to test the efficacy of a novel immunosuppressive agent, belumosudil, in allogeneic hematopoietic stem cell transplant (HSCT) recipients who have been newly diagnosed or have developing (early stage) bronchiolitis obliterans syndrome (BOS). The name of the study d...
What is the current status of trial NCT05922761?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2024-05-31. Estimated completion is 2027-12-31.
What conditions does trial NCT05922761 study?
This clinical trial studies the following conditions: Lung Diseases, Chronic Graft Versus Host Disease, Bronchiolitis Obliterans, Bronchiolitis Obliterans Syndrome.
What interventions are being tested in trial NCT05922761?
The interventions under investigation include: Belumosudil (DRUG), Fluticasone (DRUG), Azithromycin (DRUG), Prednisone (DRUG), Montelukast (DRUG).
Who is sponsoring clinical trial NCT05922761?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05922761 being conducted?
This trial has 5 study locations across Massachusetts, Michigan, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05922761's enrollment target sits among peer trials
45 28th of 31 higher than 4 of 31 other Lung Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Mosliciguat in PH-ILD
ACTIVE NOT RECRUITING · Phase 2
-
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
COMPLETED · Phase 2
-
Real World Registry for Use of the Ion Endoluminal System
RECRUITING
-
American Lung Association (ALA) Lung Health Cohort
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI